Navigation Links
It's a knock out: eIF4E-specific anti-sense oligonucleotides knock down cancer
Date:9/4/2007

A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers. As highlighted in the accompanying commentary by Celeste Simon and colleagues from the University of Pennsylvania, Philadelphia, if the therapeutic is as effective in clinical trials as it was in mice it will be useful for the treatment of a broad range of cancers.

The growth of many tumors is promoted by increased expression of the protein eIF4E, but no eIF4E-specific therapy has yet been developed. In this study, the intravenous administration of eIF4E-specific antisense oligonucleotides (ASOs) to mice bearing human tumors substantially inhibited tumor growth. Importantly, although these ASOs also decreased eIF4E expression in normal tissues, the function of the normal tissues analyzed was not compromised. The authors therefore suggest that tumor cells are more susceptible to decreased expression of eIF4E than normal cells, meaning that eIF4E-specific ASOs should not cause damage to normal tissues.

TITLE: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

AUTHOR CONTACT:

Jeremy R. Graff
Eli Lilly and Company, Indianapolis, Indiana, USA.
Phone: (317) 277-0220; Fax: (317) 277-3652; E-mail: graff_jeremy@lilly.com.

View the PDF of this article at: https://www.the-jci.org/article.php?id=32044

ACCOMPANYING COMMENTARY:

TITLE: Taking aim at translation for tumor therapy

AUTHOR CONTACT:

M. Celeste Simon
Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: (215) 746-5532; Fax: (215) 746-5511; E-mail: celeste2@mail.med.upenn.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33107


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Alcohol a potential carcinogen: knocking on the door: pay heed!
2. Knock on the Head – No Small Thing After Al
3. Lethal Hospital Bug Tough to Knock Down, Statistics Reveal
4. The Tech Savvy Patient Knocks on the Doors of Telemedicine and Virtual Clinics
5. Knocking Out Survival Protein Could Aid Leukemia Treatment
6. Knocking Out Survival Protein Could Fight Leukemia
7. Chilean Presidents Cousin Successfully Tests Allergy Knockout Technique on Mice
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Fibroids unlikely to Turn Cancerous
10. Virus Level could Predict Cervical Cancer Risk
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an eastern ... access to asset protection and financial planning services, is teaming up with the ... lives of children with cancer and other chronic diseases. , The For A ...
(Date:6/22/2017)... IN (PRWEB) , ... June 22, 2017 , ... ... benefits advisory organization, is pleased to welcome Whipple & Company as its newest ... the clear purpose of balancing their clients’ risk while tailoring optimized benefit packages ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many physicians ... available that integrate basic science with clinical practice. Now, however, a timely review has ... clinicians with insight into the etiology of NeuP and educating preclinical scientists on its ...
(Date:6/22/2017)... ... 22, 2017 , ... A June 12 article in The Star ... apparent lack of oral hygiene by an aged parent who had recently suffered a ... a number of steps, including scheduling a dentist visit. Northridge Dental Works, a Los ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... a Texas-based health system, will present how predictive analytics drive reimbursement optimization, with ... meeting in Orlando, June 25-28. , “The traditional approach to denied and ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 More than 400 ... effort to help spread lessons learned from clinical research ... Diabetes Federation (IDF) and Eli Lilly and Company (NYSE: ... second phase of the Bringing Research in Diabetes to ... commitment to helping people with diabetes effectively manage their ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
Breaking Medicine Technology: